Header Logo

Connection

KEVIN GAREY to Adult

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Adult.
KEVIN GAREY
Connection Strength
1.261
Adult
  1. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.058
  2. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.054
  3. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence. Clin Infect Dis. 2023 12 05; 77(Suppl 6):S487-S496.
    View in: PubMed
    Score: 0.053
  4. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 09 30; 75(7):1164-1170.
    View in: PubMed
    Score: 0.049
  5. Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021; 19(1):61-72.
    View in: PubMed
    Score: 0.044
  6. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
    View in: PubMed
    Score: 0.041
  7. Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
    View in: PubMed
    Score: 0.040
  8. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. J Glob Antimicrob Resist. 2018 12; 15:41-47.
    View in: PubMed
    Score: 0.036
  9. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.036
  10. Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Ann Pharmacother. 2018 08; 52(8):754-762.
    View in: PubMed
    Score: 0.036
  11. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
    View in: PubMed
    Score: 0.032
  12. Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. Am J Health Syst Pharm. 2015 Sep 01; 72(17):1471-4.
    View in: PubMed
    Score: 0.030
  13. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
    View in: PubMed
    Score: 0.030
  14. Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. Am J Health Syst Pharm. 2015 Apr 01; 72(7):568-72.
    View in: PubMed
    Score: 0.029
  15. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
    View in: PubMed
    Score: 0.028
  16. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
    View in: PubMed
    Score: 0.027
  17. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
    View in: PubMed
    Score: 0.026
  18. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr; 83(4):294-9.
    View in: PubMed
    Score: 0.025
  19. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.024
  20. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012 Apr; 343(4):277-80.
    View in: PubMed
    Score: 0.024
  21. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
    View in: PubMed
    Score: 0.023
  22. Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses. 2012 May; 28(5):454-9.
    View in: PubMed
    Score: 0.023
  23. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
    View in: PubMed
    Score: 0.023
  24. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2009 Mar; 63(3):279-85.
    View in: PubMed
    Score: 0.019
  25. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.019
  26. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct; 70(2):142-7.
    View in: PubMed
    Score: 0.019
  27. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol. 2008 Oct; 199(4):332-7.
    View in: PubMed
    Score: 0.018
  28. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun; 28(6):699-706.
    View in: PubMed
    Score: 0.018
  29. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007 Aug; 16(8):919-27.
    View in: PubMed
    Score: 0.017
  30. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
    View in: PubMed
    Score: 0.017
  31. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection. 2006 Dec; 34(6):322-7.
    View in: PubMed
    Score: 0.016
  32. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
    View in: PubMed
    Score: 0.016
  33. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
    View in: PubMed
    Score: 0.016
  34. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 01; 43(1):25-31.
    View in: PubMed
    Score: 0.016
  35. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun; 40(6):1030-4.
    View in: PubMed
    Score: 0.016
  36. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006 May; 49(3):226-31.
    View in: PubMed
    Score: 0.016
  37. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.014
  38. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.014
  39. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest. 2004 Jan; 125(1):22-6.
    View in: PubMed
    Score: 0.013
  40. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. NPJ Biofilms Microbiomes. 2023 08 03; 9(1):54.
    View in: PubMed
    Score: 0.013
  41. Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2023 09; 44(9):1403-1409.
    View in: PubMed
    Score: 0.013
  42. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection. Clin Infect Dis. 2022 07 06; 74(12):2142-2149.
    View in: PubMed
    Score: 0.012
  43. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2022 10; 43(10):1339-1344.
    View in: PubMed
    Score: 0.012
  44. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):e1029-e1044.
    View in: PubMed
    Score: 0.011
  45. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):755-757.
    View in: PubMed
    Score: 0.011
  46. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy. 2001 Jun; 21(6):748-50.
    View in: PubMed
    Score: 0.011
  47. Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students' Intention to Attend Lectures. Am J Pharm Educ. 2020 05; 84(5):7550.
    View in: PubMed
    Score: 0.010
  48. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother. 1999 May; 43(5):1152-5.
    View in: PubMed
    Score: 0.010
  49. Azathioprine hypersensitivity reaction in a patient with ulcerative colitis. Ann Pharmacother. 1998 Apr; 32(4):425-8.
    View in: PubMed
    Score: 0.009
  50. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 03 19; 66(7):e1-e48.
    View in: PubMed
    Score: 0.009
  51. Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018 Nov; 24(11):1190-1194.
    View in: PubMed
    Score: 0.009
  52. Investigating inpatient medication administration using the theory of planned behavior. Am J Health Syst Pharm. 2017 Dec 15; 74(24):2065-2070.
    View in: PubMed
    Score: 0.009
  53. Possible interaction between imipramine and butalbital. Pharmacotherapy. 1997 Sep-Oct; 17(5):1041-2.
    View in: PubMed
    Score: 0.009
  54. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 09; 50(8):631-7.
    View in: PubMed
    Score: 0.008
  55. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan; 144(1):189-97.
    View in: PubMed
    Score: 0.007
  56. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15; 60(6):892-9.
    View in: PubMed
    Score: 0.007
  57. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun; 35(6):667-73.
    View in: PubMed
    Score: 0.007
  58. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
    View in: PubMed
    Score: 0.007
  59. Clostridium difficile-related death rates in Texas 1999-2005. J Infect. 2009 Nov; 59(5):303-7.
    View in: PubMed
    Score: 0.005
  60. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
    View in: PubMed
    Score: 0.005
  61. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
    View in: PubMed
    Score: 0.004
  62. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant. 2001 Oct; 15(5):297-308.
    View in: PubMed
    Score: 0.003
  63. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep; 21(9):1107-14.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.